Top 10 Pharmaceutical Stocks with Highest Upside: HRBR, ARYX, PRAN, XOMA, PIP, DARA, CXM, CBRX, BIOD, MRNAD (Jul 26, 2010)
"Strong Buy" Rated U.S.-Listed Chinese Stocks (February 8, 2012)
Below are the top 10 Pharmaceutical stocks with highest upside potential, based on the difference between current price and Wall Street analysts' average target price.
Harbor BioSciences, Inc. (NASDAQ:HRBR) has the 1st highest upside potential in this segment of the market. Its upside is 1969.7%. Its consensus target price is $6.00 based on the average of all estimates. ARYx Therapeutics, Inc. (NASDAQ:ARYX) has the 2nd highest upside potential in this segment of the market. Its upside is 1022.4%. Its consensus target price is $5.50 based on the average of all estimates. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) has the 3rd highest upside potential in this segment of the market. Its upside is 545.2%. Its consensus target price is $8.00 based on the average of all estimates. XOMA Limited (NASDAQ:XOMA) has the 4th highest upside potential in this segment of the market. Its upside is 486.9%. Its consensus target price is $1.98 based on the average of all estimates. PharmAthene, Inc. (AMEX:PIP) has the 5th highest upside potential in this segment of the market. Its upside is 382.8%. Its consensus target price is $7.00 based on the average of all estimates.
DARA BioSciences, Inc. (NASDAQ:DARA) has the 6th highest upside potential in this segment of the market. Its upside is 352.0%. Its consensus target price is $16.00 based on the average of all estimates. Cardium Therapeutics Inc. (NYSE:CXM) has the 7th highest upside potential in this segment of the market. Its upside is 328.6%. Its consensus target price is $1.50 based on the average of all estimates. Columbia Laboratories Inc. (NASDAQ:CBRX) has the 8th highest upside potential in this segment of the market. Its upside is 325.5%. Its consensus target price is $4.00 based on the average of all estimates. Biodel Inc (NASDAQ:BIOD) has the 9th highest upside potential in this segment of the market. Its upside is 298.9%. Its consensus target price is $15.00 based on the average of all estimates. Marina Biotech, Inc. (NASDAQ:MRNAD) has the 10th highest upside potential in this segment of the market. Its upside is 292.2%. Its consensus target price is $10.67 based on the average of all estimates.
